DHR— AI Stock Forecast & Price Targets
Published 7/31/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live DHR price forecast →
DHR shows signs of mean-reversion after a post-earnings selloff, with technicals suggesting near-term upside toward $200 but valuation remains elevated at 34.8x P/E. Recent news highlights potential undervaluation and strong buyback activity, though growth deceleration and sector headwinds temper enthusiasm.
Hold near $195-200; invalidation below $185 would trigger trimming. Target: $200 in 4 weeks if price holds above $195 resistance.
Accumulate on dips to $190-$195; catalysts include Q3 earnings and buyback activity. Expect 10-15% upside over 6 months if growth stabilizes, but risk of further selloff if guidance misses.
Long-term thesis hinges on execution in diagnostics and life sciences segments. Structural risks include slowing healthcare innovation and competitive pressures from biotech firms; terminal value depends on maintaining market share in high-growth areas like AI-driven diagnostics.
Revenue grew 4.56% YTD (Q2: +5.54%), but net margins declined to 15.95% from 17.29% in Q1, reflecting margin pressure. Balance sheet remains strong with $137.90B market cap and low debt-to-equity (0.53), though free cash flow has dropped to $1.26B vs prior quarter. Buybacks are active but growth is decelerating; the 2026 guidance of 2-3% revenue growth suggests a slowdown from previous years. The PEG ratio of 2.30 indicates potential overvaluation relative to growth expectations.
Price has rebounded from $160.93 (52-week low) to $196.17, breaking above the $195 support level. The Kronos AI forecast shows a tight band between $195 and $203 for near-term, with actual price trading within this range. RSI at 53.51 suggests neutral momentum but not overbought; however, the model's directional accuracy is only 54% on 1d horizon (vs naive baseline), indicating limited reliability for short-term moves. The $200 level acts as a key resistance with potential breakout toward $227 target.
The most relevant news is Danaher's Q2 results showing revenue growth of 5.54% and net income of $870M, though the stock has underperformed YTD (-14.31%). Analysts highlight a potential undervaluation at 16% below target price ($227 vs current $196), but recent earnings selloff suggests volatility. The Kronos forecast shows a tight band around $195-$203, aligning with the technical breakout above $195.
- Q3 revenue guidance of 2-3% growth suggests stabilization after previous slowdowns
- Active buyback program (10.1M shares) to reduce float and boost EPS
- Valuation at 34.8x P/E is elevated vs sector average; PEG ratio of 2.30 indicates potential overvaluation
- Sector headwinds from healthcare regulation and pricing pressures could impact margins
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord